? Clear Development Path Forward for XRx-101 ? ? Clear Development Path Forward for XRx-101 ?
Excerpt from:
XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Go here to see the original:
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in...
MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will be a participant on the panel titled “Emerging Companies” at the Targeting Metabesity Conference, being held virtually on October 12-15, 2020. A live webcast of the presentation will be available for attendees who register at http://www.metabesity2020.com/register.html. Viewing is complimentary.
See the article here:
CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference
WATERTOWN, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public offering of 11.04 million shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1.44 million additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to C4T from the offering were $209.76 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by C4T.
The rest is here:
C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company is presenting an e-poster at the virtual Therapeutics for COVID-19 meeting held by the International Society for Influenza and other Respiratory Virus Diseases-Antiviral Group (ISIRV-AVG), taking place October 6 – 8 from noon to 4 p.m. GMT.
Orphazyme A/SCompany announcement No. 64/2020 Company Registration No. 32266355
WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the closing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $25.00 per share, before underwriting discounts and commissions. All of the shares in the public offering were sold by Arcutis. The gross proceeds from the public offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Arcutis, were $100.0 million. In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of Arcutis’ common stock at the public offering price less the underwriting discounts and commissions.
DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting. The CNS-ICNA annual meeting is being held virtually from October 12th through October 23rd, 2020. A copy of the posters will be made available on the Zynerba corporate website at the time of presentation on Monday October 12th at http://zynerba.com/publications/.
Continue reading here:
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International...
Ljubljana, Slovenia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares.
See the original post here:
Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov